Gilead Sciences draws Cantor support, shares sit below $155 target

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 09:22.

Gilead Sciences (US3755581036) stays on the radar of Wall Street as Cantor Fitzgerald reiterates its Overweight rating and a $155 price target on the NASDAQ-listed biotech, according to a recent analyst note on Investing.com. The call comes with Gilead shares last quoted at around $124.87 on June 22 on Nasdaq data, keeping a double-digit gap to the target.

Cantor Fitzgerald sticks to Overweight

Cantor Fitzgerald maintains an Overweight rating on Gilead Sciences and sets its price target at $155 per share, highlighting upside versus the current market capitalization of roughly $153.7 billion. The note flags a dividend yield of about 2.6 percent and emphasizes 11 consecutive years of dividend increases as a key appeal for income-focused investors.

The research house also points to valuation metrics, with Gilead trading at a relatively modest price-earnings multiple compared with some large-cap biotech peers such as GSK and Bristol Myers, according to the Investing.com summary. Cantor’s stance aligns with a broader constructive view in parts of the analyst community on Gilead’s HIV franchise and its late-stage pipeline.

Pipeline, PrEP and antiviral backdrop

Beyond the rating, recent reports highlight Gilead’s regulatory and clinical pipeline, especially in HIV prevention and treatment. A Zacks and Yahoo Finance-based overview notes that the U.S. Food and Drug Administration has accepted a supplemental drug application for a 300 mg tablet regimen branded as Yezugo, designed as a potential once-weekly oral PrEP option for HIV prevention, with a target FDA action date set for February 2, 2027.

The same coverage references clinical work on lenacapavir in combination regimens with Merck, where trials such as EVOKE-03 delivered a mixed picture, showing encouraging HIV results but negative outcomes in small cell lung cancer. Separately, Gilead has donated thousands of vials of its antiviral remdesivir to support the response to an Ebola outbreak in Africa, underlining the group’s continued role in global infectious-disease initiatives.

How Gilead makes its money

Gilead Sciences generates most of its revenue from antiviral medicines, led by HIV therapies such as Biktarvy and Descovy, chronic hepatitis C treatments and cell therapies in oncology. The company is increasingly investing in long-acting HIV prevention, including lenacapavir-based regimens and oral PrEP candidates like Yezugo, to extend its HIV leadership beyond daily pill formats.

Where the Gilead shares trade

The Gilead Sciences shares (US3755581036) trade on NASDAQ at $124.87 as of 2026-06-22, 16:00 New York time.

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities.